Total DSM Group at a glance

Overview of our business & performance

A broad, global nutrition business and a focused, high-quality, specialty materials portfolio

Royal DSM is a global purpose-led, science-based company in Nutrition, Health and Bioscience. DSM’s purpose is to create brighter lives for all. With its products and solutions DSM addresses some of the world’s biggest challenges whilst creating simultaneously economic, environmental and societal value for all its stakeholders; customers, employees, shareholders, and society-at-large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.

2021 key data

Group

€9,204m

Net sales

€8,106 in 2020

€1,814m

Adjusted EBITDA

€1,534 in 2020

19.7%

Adjusted EBITDA margin

18,9% in 2020

Nutrition

€7,031m

Net sales

€6,365 in 2020. >80% of group net sales

€1,447m

Adjusted EBITDA

€1,338 in 2020

20.6%

Adjusted EBITDA margin

21.0% in 2020 & an ambition of >20%

Materials

€1,935m

Net sales

€1,518 in 2020

€435m

Adjusted EBITDA

€272 in 2020

22.5%

Adjusted EBITDA margin

17.9% in 2020

People

0.22

Frequency Index of Recordable Injuries

0.24 in 2020

76%

Employee Engagement Index

76% in 2020

23%

Female executives

21% in 2020

30:70

Female:male ratio

29:71 in 2020

77%

Inclusion Index

75% in 2020

100%

Employees

offered immunity-optimizing supplements

Planet

27%

Absolute reduction

Scope 1 + 2 GHG emissions (2016 baseline)

~23%

Structural improvement

Scope 1 + 2 GHG emissions (2016 baseline)

8%

Intensity improvement

Scope 3 GHG emissions (2016 baseline)

72%

Purchased electricity

From renewable resources

6.0%

Energy efficiency

Improvement year-on-year

7.8%

Water efficiency

Improvement year-on-year

Profit

↑42.8%

Total Shareholder Return

vs. 2020

↑14%

Sales

continuing operations vs. 2020

↑18%

Adjusted EBITDA

continuing operations vs. 2020

€949m

Adjusted net operating free cash flow

€858m

Net profit from continuing operations

€2.50

Proposed dividend per ordinary share

Latest financial & regulatory news

Managing Board

Geraldine Matchett, Co-CEO

Geraldine Matchett is Co-Chief Executive Officer, Chief Financial Officer and Member of the Managing Board. She was appointed as Co-CEO on 15 February 2020 and joined DSM’s Managing Board in 2014. Her current term will end in 2022.

Dimitri de Vreeze, Co-CEO

Dimitri de Vreeze is Co-Chief Executive Officer, Chief Operating Officer and Member of the Managing Board. He was appointed as Co-CEO on 15 February 2020 and joined DSM’s Managing Board in 2013. His current term will end in 2021.

Read more